Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy

Yoshiaki Kawano, Wataru Takahashi, Masatoshi Eto, Tomomi Kamba, Hideaki Miyake, Masato Fujisawa, Takao Kamai, Hirotsugu Uemura, Taiji Tsukamoto, Haruhito Azuma, Akio Matsubara, Kazuo Nishimura, Tsuyoshi Nakamura, Osamu Ogawa, Seiji Naito

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The RCC-SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first-line interferon-α (IFN-α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log-rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group-performance status (ECOG-PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C-reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first-line IFN-α using large cohort of the prospective study. The present study suggests that first-line IFN-α is still a useful therapy for mRCC even in the era of molecular targeted therapy.

Original languageEnglish
Pages (from-to)1013-1017
Number of pages5
JournalCancer Science
Volume107
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Molecular Targeted Therapy
Renal Cell Carcinoma
Interferons
Survival
Hypercalcemia
Therapeutics
Single Nucleotide Polymorphism
Blood Vessels
Neoplasm Metastasis
Proportional Hazards Models
Thrombocytopenia
C-Reactive Protein
Anemia
Cohort Studies
Multivariate Analysis
Lymph Nodes
Demography
Prospective Studies
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy. / Kawano, Yoshiaki; Takahashi, Wataru; Eto, Masatoshi; Kamba, Tomomi; Miyake, Hideaki; Fujisawa, Masato; Kamai, Takao; Uemura, Hirotsugu; Tsukamoto, Taiji; Azuma, Haruhito; Matsubara, Akio; Nishimura, Kazuo; Nakamura, Tsuyoshi; Ogawa, Osamu; Naito, Seiji.

In: Cancer Science, Vol. 107, No. 7, 01.07.2016, p. 1013-1017.

Research output: Contribution to journalArticle

Kawano, Y, Takahashi, W, Eto, M, Kamba, T, Miyake, H, Fujisawa, M, Kamai, T, Uemura, H, Tsukamoto, T, Azuma, H, Matsubara, A, Nishimura, K, Nakamura, T, Ogawa, O & Naito, S 2016, 'Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy', Cancer Science, vol. 107, no. 7, pp. 1013-1017. https://doi.org/10.1111/cas.12951
Kawano, Yoshiaki ; Takahashi, Wataru ; Eto, Masatoshi ; Kamba, Tomomi ; Miyake, Hideaki ; Fujisawa, Masato ; Kamai, Takao ; Uemura, Hirotsugu ; Tsukamoto, Taiji ; Azuma, Haruhito ; Matsubara, Akio ; Nishimura, Kazuo ; Nakamura, Tsuyoshi ; Ogawa, Osamu ; Naito, Seiji. / Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy. In: Cancer Science. 2016 ; Vol. 107, No. 7. pp. 1013-1017.
@article{c3f4609c9adf400992d9c15ffafcc5f0,
title = "Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy",
abstract = "The RCC-SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first-line interferon-α (IFN-α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log-rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group-performance status (ECOG-PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C-reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first-line IFN-α using large cohort of the prospective study. The present study suggests that first-line IFN-α is still a useful therapy for mRCC even in the era of molecular targeted therapy.",
author = "Yoshiaki Kawano and Wataru Takahashi and Masatoshi Eto and Tomomi Kamba and Hideaki Miyake and Masato Fujisawa and Takao Kamai and Hirotsugu Uemura and Taiji Tsukamoto and Haruhito Azuma and Akio Matsubara and Kazuo Nishimura and Tsuyoshi Nakamura and Osamu Ogawa and Seiji Naito",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/cas.12951",
language = "English",
volume = "107",
pages = "1013--1017",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy

AU - Kawano, Yoshiaki

AU - Takahashi, Wataru

AU - Eto, Masatoshi

AU - Kamba, Tomomi

AU - Miyake, Hideaki

AU - Fujisawa, Masato

AU - Kamai, Takao

AU - Uemura, Hirotsugu

AU - Tsukamoto, Taiji

AU - Azuma, Haruhito

AU - Matsubara, Akio

AU - Nishimura, Kazuo

AU - Nakamura, Tsuyoshi

AU - Ogawa, Osamu

AU - Naito, Seiji

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The RCC-SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first-line interferon-α (IFN-α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log-rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group-performance status (ECOG-PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C-reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first-line IFN-α using large cohort of the prospective study. The present study suggests that first-line IFN-α is still a useful therapy for mRCC even in the era of molecular targeted therapy.

AB - The RCC-SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first-line interferon-α (IFN-α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log-rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group-performance status (ECOG-PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C-reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first-line IFN-α using large cohort of the prospective study. The present study suggests that first-line IFN-α is still a useful therapy for mRCC even in the era of molecular targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=84978807206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978807206&partnerID=8YFLogxK

U2 - 10.1111/cas.12951

DO - 10.1111/cas.12951

M3 - Article

VL - 107

SP - 1013

EP - 1017

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -